An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer
Clinical trial NCT05356351 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT05356351
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-01
- Primary completion
- 2023-07-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.